Carrier Screening Market Analysis

Carrier Screening Market Analysis

Based on type, the carrier screening market is segmented into targeted disease carrier screening and expanded carrier screening. The expanded carrier screening segment accounted for majority revenue share in 2022 and is expected to reach around USD 3.7 billion in 2032. This is primarily attributed to the fact that it is used in screening of multiple genetic disorders irrespective of the person's ethnic background. Expanded carrier screening panels use different type of new high-throughput technologies such as microarrays and sequencing. Additionally, launch of novel products is further anticipated to boost the segmental growth.
 

Based on technology, the market is categorized into polymerase chain reaction, microarrays, DNA sequencing, and others. The DNA sequencing segment held the leading revenue share and was valued at around USD 637 million in 2022. Increasing adoption of advanced techniques such the next-generation sequencing (NGS) technology and chromosomal microarrays are among the primary growth drivers boosting the segmental progression. The NGS technology aid in understanding of whole-genome sequencing to detect gene complications. It further helps in understanding the genome, epigenome and transcriptome of the person undergoing screening test. Hence, the afore-mentioned variables are projected to fuel the market growth over the forecast period.
 

Based on medical condition, the market is segregated into hematological conditions, neurological conditions, pulmonary conditions, and others. Pulmonary conditions segment dominated the carrier screening market in terms of revenue and was valued at USD 679 million in 2022. Carrier screening is majorly used for detection of different pulmonary conditions primarily for cystic fibrosis. It is an inherited disease caused due to mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
 

Based on end-use, the carrier screening market is bifurcated into hospitals, reference laboratories, physician offices & clinics, and others. The hospitals segment held a significant revenue share in 2022 and is anticipated to witness healthy growth with a CAGR of 13.5% throughout the forecast period. Increase in availability of range of genetic testing services portfolio is among the key factor for growing preference of patient population towards hospitals. Additionally, increasing awareness level, availability, and adoption of advanced carrier screening technologies, rise in overall genetic disease prevalence, presence of well-trained and equipped healthcare personnel, is projected to boost the segmental sales.
 

North America region held the dominating revenue share in the global carrier screening market and is expected to reach over USD 2.3 billion in 2032. Increase in R&D spending for different genetic complications, availability of wide range of carrier screening products are projected to support the regional growth trend. Favorable demographic trends including presence of significant patient pool, demand for direct-to consumer genetic testing model, and high adoption rate for prenatal and new-born genetic testing in the U.S. is expected to boost the market growth. Additionally, presence of significant target population is among the key driving factor for regional development.